Patents

US 11690825 B2: 20-HETE receptor (GPR75) antagonists and methods of use

Granted
2023-07-04
Filed
2017-03-08 application 16083404
Type
Utility · 28 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

The present invention concerns compounds and their use to treat cardiovascular disease, renal disease, thrombic disease, stroke, metabolic syndrome, cell proliferation, and ischemic cardiovascular disorders. Compounds of the present invention display significant potency as antagonists of 20-hydroxyeicosatetraenoic acid (20-HETE), and function as anti-hypertensive, anti-inflammatory, or anti-growth agents.

Source: PVGPATDIS, file of 2026-04-10 (ipg230704.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 3,356 patentsUS company or organizationAustin, TXPVGPATDIS, file of 2026-04-10
NEW YORK MEDICAL COLLEGE 19 patentsUS company or organizationValhalla, NYNew York Medical College College or university EXACT high confidence: identical full name and state
NEW YORK MEDICAL COLLEGE Nonprofit EXACT high confidence: identical full name and state
PVGPATDIS, file of 2026-04-10

Inventors

InventorPlacePatentsPerson pageSource
John R. FalckAustin, TX20PVGPATDIS, file of 2026-04-10
Michal L. SchwartzmanValhalla, NY1Person page FUZZY medium confidencePVGPATDIS, file of 2026-04-10
Victor GarciaValhalla, NY5PVGPATDIS, file of 2026-04-10

CPC categories

SubclassCategoryFirst groupSource
G01NInvestigating or analysing materials by determining their chemical or physical propertiesG01N33/92PVGPATDIS, file of 2026-04-10
A61KPreparations for medical, dental or toiletry purposesA61K31/231PVGPATDIS, file of 2026-04-10
C07CAcyclic or carbocyclic compoundsC07C57/52PVGPATDIS, file of 2026-04-10
C40BCombinatorial chemistry; libraries, e.g. chemical librariesC40B30/04PVGPATDIS, file of 2026-04-10
A61PSpecific therapeutic activity of chemical compounds or medicinal preparationsA61P13/12PVGPATDIS, file of 2026-04-10
C07BGeneral methods of organic chemistry; apparatus thereforC07B2200/07PVGPATDIS, file of 2026-04-10
C07DHeterocyclic compoundsC07D257/04PVGPATDIS, file of 2026-04-10
C07KPeptidesC07K14/723PVGPATDIS, file of 2026-04-10

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2025-02-24Assignment
Assignment of assignor's interest
GARCIA, VICTOR signed 2016-05-05
SCHWARTZMAN, MICHAL L. signed 2017-01-04
NEW YORK MEDICAL COLLEGE VALHALLA, NY70305/367ECORSEXC, file of 2026-09-25
2025-02-24Assignment
Assignment of assignor's interest
FALCK, JOHN R. signed 2016-03-23BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM AUSTIN, TX70305/20ECORSEXC, file of 2026-09-25

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.